Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System
This study has been completed.
Information provided by (Responsible Party):
University of Colorado, Denver
First received: December 12, 2011
Last updated: March 6, 2013
Last verified: December 2012
The PharmaJet needle-free injection system is a consistent approach to delivering injectates into the dermal layer of the human skin for the purpose of vaccination or medication delivery.
Functionality and Performance of Device
||Observational Model: Case-Only
Time Perspective: Prospective
||Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System
Primary Outcome Measures:
- Completeness of injection [ Time Frame: within one minute after injection ] [ Designated as safety issue: No ]
To assess measures of injection performance, including estimates of injection completeness by collecting residual surface moisture with filter paper that will be circled with indelible ink; the volume will be compared to a reference set of moisture recordings. Measurement of the bleb size following injection will recorded in millimeters.
- Size of bleb on skin after injection [ Time Frame: within 2 minutes after injection ] [ Designated as safety issue: No ]
Measurement of the bleb size immediately following injection will be determined using a millimeter ruler
- Acceptability by subject [ Time Frame: up to 48 hrs ] [ Designated as safety issue: No ]
subjects response to the injection-level of pain or discomfort. Subjects response will not be collected for those who opt to receive the injections while under anesthesia.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2012 (Final data collection date for primary outcome measure)
90 pediatric, 7 to 14 year old subjects
30 pediatric, 5 to 6 year old subjects
30 pediatric, 3 to 4 year old subjects
30 pediatric, 1 to 2 year old subjects
30 pediatric, 6 to 12 month old subjects
30 pediatric, 4 to 6 month old subjects
30 pediatric, 2 to 4 month old subjects
Up to 400 children, ages 2 months through 14 years
- To assess measures of injection performance, including estimates of injection completeness by collecting residual surface moisture with filter paper that will be circled with indelible ink; the volume will be compared to a reference set of moisture recordings.
- To document completeness of injections; completeness is defined as <10% of 0.1 ml volume remaining on the skin surface immediately after injection. Measurement of the bleb size following injection will recorded in millimeters.
- To ensure device is well received by subjects. Subject's response to the injection will be noted by the subject and/or family members after the procedure for up to 48 hours.
|Ages Eligible for Study:
||2 Months to 14 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Up to 400 children, aged 2 months to 14 years
- Infants and children between ages 2 months and 14 years
- Outpatient, expected to go home day of surgery
- Written consent and assent when appropriate
- Willing to complete and return pain diary (postcard) after 48 hours
- Presently have skin rash at the intended injection site
- Have a history of use of any topical or systemic medications at the intended injection site that could have potentially altered the normal physical properties of the skin (i.e. atrophy from chronic steroid use, thinning of the skin from topical or systemic retinoids).
- Have a permanent physical change in the skin at the intended injection site, such as burns, scars or prior radiation therapy.
- Skin disorders that may predispose them to develop skin lesions at sites of trauma.
- Present use of any blood thinning medications.
- In the 10-11 year old cohort, none of the participants can have started puberty.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01494571
|Children's Hospital Colorado
|Aurora, Colorado, United States, 80045 |
University of Colorado, Denver
||Jeffrey Galinkin, MD
||Children's Hospital Colorado
No publications provided
ClinicalTrials.gov processed this record on October 20, 2014
||University of Colorado, Denver
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 12, 2011
||March 6, 2013
||United States: Institutional Review Board